


# Image Cover Sheet

<b>CLASSIFICATION</b>  UNCLASSIFIED	<b>SYSTEM NUMBER</b> 149586 
---	--

**TITLE**  
MILITARY SIGNIFICANT VACCINES

**System Number:**  
**Patron Number:**  
**Requester:**

**Notes:**

**DSIS Use only:**  
**Deliver to:** DK



#149586

**Annex I**

10 pages in total





**National Defence**  
Research and  
Development Branch

**Défense Nationale**  
Bureau de Recherche  
et Développement

## **Militarily Significant Vaccines**

by

**L. A. White**  
**DRDHP**

**Directorate**  
**Research and**  
**Development**  
**Human**  
**Performance**

**Direction-**  
**Recherche et**  
**développement**  
**Performances**  
**Humaines**

**Canada**

*Militarily Significant Vaccines*

## **Objective**

- To develop a series of vaccines which will be effective against the range of potential BW agents identified by ITF-6
- Probable joint program with U.S. and UK

## Background

- At present there are vaccines for only a small number of the identified biological threat agents
- Many of the existing vaccines have limited or unknown efficacy especially in the face of aerosol challenge
- There is little industrial vaccine R&D activity on agents of concern since they are essentially limited to military use and so there is limited potential for profit

## Background cont'd

- **None of CA/UK/US possess adequate vaccine production capability which is available for production of military vaccines**
- **During the Gulf War, it was established that no suitable Canadian industry existed which was willing to undertake the production required.**
- **U.S. looking at options for a vaccine production facility for military vaccines (COCO or GOCO)**



## Background cont'd

- UK is at a similar stage as CA ie. in the process of evaluating their capabilities and determining how to improve them
- This is a perceived opportunity for Canadian Biotechnology companies to demonstrate their capabilities
- Serious interest has been expressed by several potential producers with veterinary vaccine capability
- Technology will have application to the Biological and Toxin Weapons Convention

*Militarily Significant Vaccines*

## Present Status

- SCD - Vaccines for Biological Warfare Agents (pending approval)
- DCDS Policy on Immunization being prepared with completion by 1 Sep 94
- Approval of PCP for 1A project expected by December 1996.

## Conduct

- A joint solution is being investigated under the US/UK/CA MOU on CB Defence
  - It will be necessary to identify competent Canadian Centres of Excellence and potential producers of these vaccines.
  - Collaborate with other government departments, appropriate institutes and industries to expand/establish their capabilities to meet the vaccine needs of the CF
  - Level of support required will be determined as a priority as part of a lead-in 1B project

*Militarily Significant Vaccines*

## Resources Required

- Estimated total resources for Canadian portion - \$20M
  - DND - \$4M
  - Industry - \$10M
  - Other Government Agencies - \$6M

## 1A Funding

- FY 96/97 - \$500K
- FY 97/98 - \$1750K
- FY 98/99 - \$1500K
- FY 99/00 - \$250K

*Militarily Significant Vaccines*

## Related 1B Projects

- 0518B - Liposome-Encapsulated/Associated Antigens as Vaccines for BW Agents
- 0519T - Extending the Shelf Life of Vaccines
- 0520A - Clinical Trails of Half Dose Hepatitis B Vaccine in Young, Non-Obese CF Members
- 0520B - Development of Passive Immunization to Western Equine Encephalitis Virus
- 0520? - Feasibility Study for the Development of a Canadian BW Vaccine Production Capability